LYRA250516C2000
- 0.75
- 0.000.00%
Lyra Therapeutics Newsroom
BTIG Initiates Lyra Therapeutics(LYRA.US) With Hold Rating
BTIG Keeps Their Hold Rating on Lyra Therapeutics (LYRA)
Analysts Offer Insights on Healthcare Companies: Inogen (INGN) and Lyra Therapeutics (LYRA)
Lyra Therapeutics Announces It Will Present 52-Week Extension Stage Results For ENLIGHTEN 1 Phase 3 Study For LYR-210 For The Treatment of Chronic Rhinosinusitis At COSM May 14-18 2025 In New Orleans
Lyra Therapeutics GAAP EPS of -$0.13 Beats by $0.01, Revenue of $0.18M Beats by $0.02M
Lyra Therapeutics | 10-Q: Q1 2025 Earnings Report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Press Release: Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics 1Q Loss $8.55M >LYRA
Lyra Therapeutics 1Q Loss/Shr 13c >LYRA
William Blair Initiates Lyra Therapeutics(LYRA.US) With Hold Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), ATyr Pharma (ATYR) and Lyra Therapeutics (LYRA)
Express News | HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target
Lyra Therapeutics Analyst Ratings
Lyra Therapeutics (LYRA) Gets a Hold From William Blair
Lyra Therapeutics FY 2024 GAAP EPS $(1.43) Misses $(1.38) Estimate, Sales $1.534M Beat $1.524M Estimate
Lyra Therapeutics | 10-K: FY2024 Annual Report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Press Release: Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Express News | Lyra Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "SCAFFOLD LOADING AND DELIVERY SYSTEMS (FOR TUBULAR IMPLANTS)"